VKTX logoVKTX
Viking Therapeutics Inc

36,218
Loading...
Loading...
News
all
press releases
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
Zacks·8h ago
News Placeholder
More News
News Placeholder
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Zacks·1d ago
News Placeholder
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Zacks·2d ago
News Placeholder
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Zacks·2d ago
News Placeholder
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) reached $24.09 at the closing of the latest trading day, reflecting a -2.92% change compared to its last close.
Zacks·3d ago
News Placeholder
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
Zacks·3d ago
News Placeholder
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
Zacks·7d ago
News Placeholder
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Zacks·8d ago
News Placeholder
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks·9d ago
News Placeholder
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.48, indicating a -5.56% shift from the previous trading day.
Zacks·10d ago

Latest VKTX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.